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Abstract
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive
sarcomas that arise sporadically or in association with the Neurofibromatosis type
1 (NF1) cancer predisposition syndrome. In individuals with NF1, MPNSTs are
hypothesized to arise from Nf1-deficient Schwann cell precursor cells following the
somatic acquisition of secondary cooperating genetic mutations (e.g., p53 loss). To
model this sequential genetic cooperativity, we coupled somatic lentivirus-mediated
p53 knockdown in the adult right sciatic nerve with embryonic Schwann cell precursor
Nf1 gene inactivation in two different Nf1 conditional knockout mouse strains. Using
this approach, ~60% of mice with Periostin-Cre-mediated Nf1 gene inactivation
(Periostin-Cre; Nf1flox/flox mice) developed tumors classified as low-grade MPNSTs
following p53 knockdown (mean, 6 months). Similarly, ~70% of Nf1+/- mice with
GFAP-Cre-mediated Nf1 gene inactivation (GFAP-Cre; Nf1flox/null mice) developed lowgrade MPNSTs following p53 knockdown (mean, 3 months). In addition, wild-type and
Nf1+/- mice with GFAP-Cre-mediated Nf1 loss develop MPNSTs following somatic p53
knockout with different latencies, suggesting potential influences of Nf1+/- stromal
cells in MPNST pathogenesis. Collectively, this new MPNST model system permits the
analysis of somatically-acquired events as well as tumor microenvironment signals
that potentially cooperate with Nf1 loss in the development and progression of this
deadly malignancy.

INTRODUCTION

plexiform neurofibromas in childhood is uncommon, the
development of pain or motor weakness associated with
a pre-existing plexiform neurofibroma in a teenager or
young adult should prompt evaluation for a MPNST. In
patients with these malignant tumors, overall survival is
poor, and successful treatment options are limited. Even
when surgery is employed in combination with radiation
or chemotherapy, ~50% of individuals will experience
local recurrence as well as distant metastases, and the
majority will succumb to their cancer within 5 years [1-3].
MPNSTs occur most frequently in the setting of

MPNSTs are an aggressive subtype of soft-tissue
sarcoma that develops in association with peripheral
nerves or nerve roots. Composed of neoplastic
Schwann cells, these malignancies are thought to arise
from benign nerve sheath tumors, termed plexiform
neurofibromas. Plexiform neurofibromas are frequently
detected during early childhood, raising the possibility
that they are congenital tumors that initiate during fetal
or early postnatal life. While transformation of these
www.impactjournals.com/oncotarget
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the Neurofibromatosis 1 (NF1) tumor predisposition
syndrome, affecting approximately 8-13% of people with
NF1 [4]. Individuals with NF1 are born with a germline
mutation in one copy of the NF1 gene, such that all
cells in their bodies have one dysfunctional NF1 allele.
However, tumorigenesis requires somatic loss of the other
NF1 allele in the appropriate cell of origin. Consistent
with a key role for the NF1 gene in both NF1-associated
and sporadic MNPST pathogenesis, bi-allelic NF1 gene
inactivation has been reported in approximately 60-90%
of NF1-associated MPNSTs and 40-60% of sporadic
cases [5, 6]. While loss of NF1 gene expression is
required for MPNST development, it is not sufficient. As
such, MPNST formation requires additional cooperating
genetic events, the most frequent of which is mutational
inactivation of the TP53 tumor suppressor gene, occurring
in approximately 75% of cases [7-9].
In this regard, genetically-engineered mouse (GEM)
lines with conditional Nf1 gene inactivation in Schwann
cell precursors do not develop MPNSTs [10-14] unless
coupled with concomitant Trp53 loss [15, 16], epidermal
growth factor receptor (Egfr) amplification [7, 17], Pten
loss [18], or Ink4a deletion [19, 20]. In each of these GEM
strains, the cooperating genetic mutation was introduced
simultaneously with Schwann cell precursor Nf1 gene
inactivation throughout the body. While each of these
models has been informative for understanding MPNST
pathogenesis, they do not permit temporal (timing of the
cooperating somatic genetic change) or spatial (specific
nerve location) control over MPNST development.
To generate a model in which temporal control of the
transforming genetic alteration can be achieved in a single
nerve location, we employed two GEM strains in which
Cre-mediated Nf1 inactivation occurs in Schwann cell
precursor cells during embryogenesis and p53 knockdown
is somatically acquired at 6-8 weeks of age in cells
within the right sciatic nerve. Using this approach, 6070% of mice develop sciatic nerve MPNSTs associated
with focal neurological dysfunction. The coupling of
somatic retroviral knockdown and embryonic Nf1 gene
inactivation establishes an experimentally-manipulable
platform to evaluate other cooperating genetic changes in
MPNST pathogenesis as well as preclinical mouse strains
in which clinical symptomatology can be used to monitor
tumor progression.

benign plexiform neurofibroma to a MPNST. In addition,
loss of one copy of the TP53 gene was only detected at the
MPNST stage [21]. These observations in a single patient
support a model in which NF1 gene inactivation precedes
TP53 mutation in the pathogenesis of NF1-associated
MPNST.
To model this temporal sequence in mice, we
leveraged two different GEM strains in which bi-allelic
Nf1 gene inactivation occurred in Schwann cell precursors
during embryonic development. For these experiments,
Nf1flox/flox mice were intercrossed with either Periostin-Cre
[22, 23] or GFAP-Cre [24] mice to eliminate Nf1 protein
(neurofibromin) expression in Schwann cell precursors.
We first sought to generate mice with a germline null
Nf1 gene mutation and a conditional Nf1 allele; however,
the majority of Periostin-Cre; Nf1flox/null mice did not
survive to weaning age (~3-4 weeks), as previously
reported by others [23]. As such, Periostin-Cre; Nf1flox/flox
mice and GFAP-Cre; Nf1flox/null mice, were used for these
experiments. Importantly, neither strain develops MPNSTs
without the introduction of additional genetic alterations
(e.g., somatic p53 knockdown).
In the Periostin-Cre model, promoter activity is
detected as early as embryonic day 10 (E10) within
post-migratory Schwann cell progenitor cells. Based on
published reporter activity studies, recombination occurs
in the enteric nervous system, peripheral nervous system
(including Schwann cells), and within a subpopulation of
cardiac outflow tract mesenchymal cells [22]. As expected,
intercrossing Periostin-Cre mice with a Rosa-GREEN
reporter strain [25] revealed green fluorescent protein
(GFP) expression in sciatic nerves (Figure 1a). Similarly,
in the GFAP-Cre model, where promoter activity has been
reported as early as E13.5 in the brain [24], we observed
robust GFP expression in the sciatic nerves of adult GFAPCre mice following intercrossing with Rosa-GREEN
reporter mice (Figure 1a).
To determine whether Cre-mediated excision might
also occur in the hematopoietic cells that populate the
tumor microenvironment [12, 26-28] (e.g., mast cells and
macrophages), both Cre driver lines were intercrossed
with Rosa-GREEN reporter mice [25]. Whereas GFP
expression was observed within the adult sciatic nerve,
there was no GFP labeling within the bone marrow (Figure
1a). The lack of GFP expression in the bone parenchyma
demonstrates that Cre-mediated excision is largely limited
to the Schwann cell precursors within the sciatic nerve,
rather than infiltrating bone marrow-derived stromal cells
in the tumor microenvironment.
Western blot analysis of the sciatic nerves
of Periostin-Cre; Nf1flox/flox mice revealed loss of
neurofibromin expression, but intact p53 expression
(Figure 1b). The absence of neurofibromin expression
demonstrates that early Nf1 gene inactivation in Schwann
cell precursors occurs prior to the induction of shRNA
retrovirus-mediated p53 knockdown. Similar to Periostin-

RESULTS AND DISCUSSION
Leveraging
whole
exome
sequencing
methodologies, a recent study from our laboratory
revealed a temporal sequence of genetic changes in a
single patient with progression of an NF1-associated
plexiform neurofibroma to MPNST over a 14-year period.
Analysis of these pathological specimens demonstrated an
increasing proportion of cells with a somatic NF1 gene
mutation (second hit) as the tumor progressed from a
www.impactjournals.com/oncotarget
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Cre; Nf1flox/flox mice, no neurofibromin expression was
detected in the sciatic nerves of GFAP-Cre; Nf1flox/null mice
by western blot (Figure 1b).
Next, to introduce p53 knockdown specifically in
cells within the sciatic nerve, we leveraged a lentiviral
approach in which Nf1 and Trp53 knockdown occurs
following p53 shRNA virus injection (Figure 2a). This
construct has previously been employed to reduce Nf1 and
Trp53 gene expression in the brain in vitro and in vivo,
resulting in high-grade gliomas [29]. In this regard, we
observed 40% and 70% reductions in neurofibromin and
p53 expression, respectively, in NIH-3T3 cells 96 hours
post-lentiviral infection in vitro (Figure 2b). The choice
to employ a lentivirus containing shRNAs targeting both
the Nf1 and Trp53 genes reflected a lack of reproducible
knockdown (KD) when the identical Trp53 shRNA was
employed alone (data not shown). Importantly, since Nf1
expression has already been silenced in GFAP-Cre; Nf1flox/
null
, GFAP-Cre; Nf1flox/flox, and Periostin-Cre; Nf1flox/flox
mice, the effects of shRNA Nf1 KD on the preneoplastic
Schwann cell component should be negligible.

For all MPNST induction experiments, adult sciatic
nerves were surgically isolated and injected with p53
shRNA lentivirus when the mice reached 6-8 weeks of
age. Mice were then monitored by serial examination until
they demonstrated neurological abnormalities (e.g., right
leg weakness), at which time they were euthanized for
gross pathological and histological analyses (Figure 2c).
Initial experiments used mice in which
neurofibromin expression was ablated in periostinexpressing cells, including Schwann cell precursors within
the peripheral nerves (Periostin-Cre; Nf1flox/flox mice),
consistent with previous lineage tracing studies [30].
While the precise cell of origin is not known in this model,
Cre-driven reporter expression has been observed in brain
lipid binding protein (BLBP)-immunoreactive cells, which
represent Schwann cell precursors or immature Schwann
cells [30]. To induce MPNSTs, pTomo-shNf1;shp53
lentivirus or vehicle was injected into the right sciatic
nerves of 6-8 week old Periostin-Cre; Nf1flox/flox mice,
resulting in GFP expression following Cre-mediated
recombination (Supplemental Figure 1a). Following the

Figure 1: Murine MPNST model system employed. a. Representative images of sciatic nerves and femurs (bone) from GFAP-Cre
(FVB-Tg(GFAP-cre)25Mes/J) and Periostin-Cre mice crossed to Rosa-Green reporter mice. Green fluorescent protein (GFP)-positive cells
were observed in the sciatic nerve and bone periosteum (white arrows), but not in the hematopoietic cells within the bone parenchyma.
Scale bar, 50µm. b. Western blotting reveals complete loss of neurofibromin expression and intact p53 expression in Periostin-Cre; Nf1flox/
flox
and GFAP-Cre; Nf1flox/null sciatic nerves compared to intact neurofibromin and p53 expression in the wild-type sciatic nerve.
www.impactjournals.com/oncotarget
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Figure 2: Lentiviral introduction of pTomo-shNf1;shp53 into the sciatic nerve. a. Schematic of the pTomo-shNf1;shp53
lentivirus construct used in these studies [29]. b. Western blotting demonstrates a 40% reduction in neurofibromin expression and a 70%
reduction in p53 expression 96 hours after pTomo-shNf1;shp53 lentiviral infection of NIH-3T3 cells. c. Schematic of study design. d.
Western blotting reveals complete loss of neurofibromin expression coupled with a 60% reduction in p53 expression within the sciatic
nerves of Periostin-Cre; Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus relative to uninjected control nerves. e. Western blotting
reveals complete loss of neurofibromin expression coupled with an 80% reduction in p53 expression within the sciatic nerves of GFAP-Cre;
Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus relative to uninjected control nerves.
www.impactjournals.com/oncotarget
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Table 1: MPNST development in Nf1 mutant mice following p53 knockdown
MPNST latency, mean
Mouse genotype (injection)
Hyperplasia
MPNST
days (range)
Periostin-Cre; Nf1flox/flox (vehicle)
2/11
0/11
No tumors: 83-304d*
10/18
183d (144-278d)
Periostin-Cre; Nf1flox/flox (pTomo-shNf1;shp53) 8/18
flox/null
(vehicle)
2/6
0/6
No tumors: 49-217d*
GFAP-Cre; Nf1
3/11
8/11
91d (25-211d)
GFAP-Cre; Nf1flox/null (pTomo-shNf1;shp53)
0/4
0/4
No tumors:129-153d*
GFAP-Cre; Nf1flox/flox (vehicle)
2/5
3/5
176d (117-298d)
GFAP-Cre; Nf1flox/flox (pTomo-shNf1;shp53)
Wild-type (pTomo-shNf1;shp53)
0/4
0/4
No tumors: 182-365d#
Nf1+/- (pTomo-shNf1;shp53)
0/4
0/4
No tumors: 182-365d#
*Vehicle mice were euthanized and analyzed at time points equivalent to those when p53 shRNA-injected mice were
euthanized or at a time when they became ill due to non-tumor-related issues (rectal prolapse or hydrocephalus). The details
are provided below:
Vehicle-injected GFAP-Cre; Nf1flox/null mice: 2 mice at 49 days, 2 mice at 154 days and 2 mice at 217 days.
Vehicle-injected Periostin-Cre; Nf1flox/flox mice: 1 mouse at 83 days, 3 mice at 144 days, 2 mice at 154 days, 2 mice at 230 days,
2 mice at 259 days, and 1 mouse at 304 days.
Vehicle-injected GFAP-Cre; Nf1flox/flox mice: 2 mice at 129 days, 1 mouse at 138 days, and 1 mouse at 158 days.
Wild-type and Nf1+/- mice: 2 mice at 183 days and 2 mice at 365 days for each group.
#
Wild-type and Nf1+/- mice were euthanized and analyzed at 6 month or 12 month time points, as no mice developed
symptoms or non-tumor-related issues.
injection of this lentivirus into the right sciatic nerves
of 6-8 week old mice, the pre-existing complete loss
of neurofibromin expression in these nerves was now
accompanied by a 60% reduction in p53 protein expression
within the tumors (Figure 2d). With an average latency of
183 days post-injection (Table 1), ~60% of the pTomoshNf1;shp53 lentivirus-injected Periostin-Cre; Nf1flox/flox
mice exhibited paresis of the affected leg, as evidenced
by pronounced right-sided lower extremity limping. At
this time, these mice were euthanized and their sciatic
nerves evaluated for the presence of a malignant tumor. In
10/18 of these mice, grossly-appearing mass lesions were
appreciated in the nerves of lentiviral-injected animals, but
not in the vehicle-injected controls (Figure 3a).
Neuropathological analyses of the resulting tumors
revealed striking hypercellularity, mild to moderate
nuclear pleiomorphism, reduced S100β immunopositivity,
increased Ki67 labeling (Figure 3b), infiltration of
adjacent fibroadipose tissue, and mitotic figures
(Supplemental Figure 1b), as seen in their human lowgrade MPNST counterparts. Additionally, these murine
MPNSTs retained basement membrane staining (Collagen
4A; Col4a immunoreactivity) and demonstrated mast cell
infiltration visualized by tryptase staining, as reported in
other murine MPNST-like tumors [31] (Figure 3b). Based
on the observed increased cellularity, nuclear atypia, and
mitotic activity, these lesions are most accurately classified
as low-grade MPNST, as suggested by the Comparative
Pathology of Nerve Sheath Tumors in Mouse Models
and Humans Committee Consensus Report [32]. The
remaining 8 mice exhibited hyperplasia only, similar to
some of the vehicle-injected mice.
The development of MPNSTs in mice without
complete loss of p53 expression (Figure 2d) suggests that
bi-allelic (complete) inactivation of the Trp53 gene might
www.impactjournals.com/oncotarget

not be necessary for malignant transformation. While
we cannot exclude the acquisition of additional genetic
changes that effectively abrogate p53 signaling, previous
reports in both mouse models and human pathological
MPNST specimens have likewise support the concept
that TP53 haploinsufficiency may be sufficient for
MPNST formation [7, 9]. Similarly, our recent whole
exome sequencing analysis of a single patient with NF1related plexiform neurofibroma malignant transformation
revealed only heterozygous TP53 loss [21].
The development of MPNSTs in Periostin-Cre;
Nf1flox/flox mice raises the intriguing possibility that
malignant transformation does not require heterozygous
Nf1 loss in cells within the tumor microenvironment.
While previous studies from one of our laboratories
(D.W.C.) have clearly demonstrated a critical role for
infiltrating Nf1+/- stromal cells in benign murine plexiform
neurofibroma formation and growth [12, 27, 28], the
apparent stromal independence in MPNST pathogenesis
could reflect differences between low-grade tumor growth
requirements and those operative in malignant cancers. In
this respect, similar differences have also been reported
for murine Nf1 brain tumors: Nf1+/- stromal cells are
required for low-grade murine optic glioma formation
and continued growth in vivo [33-35], but high-grade
glioblastoma development can occur following Nf1 and
p53 inactivation in nestin+ neural stem cells alone in vivo
[36].
Since the early lethality (pre-weaning) observed
in Nf1+/- mice with periostin-Cre-mediated Nf1 gene
inactivation precluded an examination of the contribution
of the Nf1+/- tumor microenvironment to MPNST biology,
we sought to reduce the latency of MPNST development
by coupling somatic retrovirus-mediated p53 knockdown
and embryonic Schwann cell precursor Nf1 gene
7407
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Figure 3: MPNST development in mice with embryonic Schwann cell precursor Nf1 loss and postnatal somatic Trp53
reduction. a. Gross images of the sciatic nerves from Periostin-Cre; Nf1flox/flox mice injected with vehicle or pTomo-shNf1;shp53 virus.

Low-grade MPNSTs were only observed in the sciatic nerves of Periostin-Cre; Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus. Scale
bar, 1000µm. b. Sciatic nerve sections from Periostin-Cre; Nf1flox/flox mice injected with pTomo-shNf1;shp53 virus demonstrate increased
cellularity, nuclear pleiomorphism, and mitotic figures, consistent with low-grade MPNST (H&E). Induced MPNSTs exhibit reduced S100
β-staining, increased Ki67 labeling, increased mast cell infiltration (tryptase staining), and collagen-4A (Col4A) basement membrane
immunoreactivity. Scale bar, 40µm.
www.impactjournals.com/oncotarget
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Figure 4: MPNST formation is accelerated in Nf1+/- mice harboring embryonic Nf1 loss and somatic Trp53 reduction.
a. Gross images of the sciatic nerves from GFAP-Cre; Nf1flox/null mice injected with vehicle or pTomo-shNf1;shp53 virus. Low-grade
MPNSTs were only observed in the sciatic nerves of GFAP-Cre; Nf1flox/null mice injected with pTomo-shNf1;shp53 virus. Scale bar, 1000µm.
b. Sciatic nerve sections from GFAP-Cre; Nf1flox/null mice injected with pTomo-shNf1;shp53 virus demonstrate increased cellularity and
nuclear pleiomorphism, consistent with low-grade MPNST (H&E). Induced MPNSTs exhibit reduced S100 β-staining, increased Ki67
labeling, increased mast cell infiltration (tryptase staining), and collagen-4A (Col4A) basement membrane immunoreactivity. Scale bar,
40µm.
www.impactjournals.com/oncotarget
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inactivation in the setting of an Nf1+/- microenvironment.
For these experiments, we employed GFAP-Cre mice [24],
in which Cre-mediated recombination occurs in the sciatic
nerve (Figure 1a). In contrast to the Periostin-Cre; Nf1flox/null
mice, the majority of which die by 4 weeks of life, Nf1flox/
null
; GFAP-Cre mice are viable into adulthood. Similar to
the experiments performed with the Periostin-Cre; Nf1flox/
flox
mice, pTomo-shNf1;shp53 lentivirus or vehicle was
injected into the sciatic nerves of 6-8 week old GFAP-Cre;
Nf1flox/null mice. Following the injection of this lentivirus
into the right sciatic nerves of 6-8 week old mice, the preexisting complete loss of neurofibromin expression in
these nerves was now accompanied by an 80% reduction
in p53 protein expression within the tumors (Figure 2e).
While none of the vehicle-injected mice exhibited any
neurological deficits, eight of eleven GFAP-Cre; Nf1flox/
null
mice injected with pTomo-shNf1;shp53 lentivirus
exhibited right leg weakness. Following euthanasia, gross
morphological features of MPNST were observed (Figure
4a). As observed with the pTomo-shNf1;shp53 lentivirusinjected Periostin-Cre; Nf1flox/flox mice, MPNSTs in the
GFAP-Cre; Nf1flox/null mice with somatic p53 knockdown
exhibited striking hypercellularity, mild to moderate
nuclear pleiomorphism, reduced S100β immunoreactivity,
increased Ki67 labeling, mast cell infiltrates (Tryptase
staining), infiltration of adjacent fibroadipose tissue, and
Col4A immunoreactivity (Figure 3b). However, in contrast
to pTomo-shNf1;shp53 lentivirus-injected Periostin-Cre;
Nf1flox/flox mice, the average time to MPNST formation was
only ~90 days as opposed to ~183 days.
It is possible that the shortened MPNST latency
observed in injected GFAP-Cre; Nf1flox/null mice reflected
growth-promoting contributions from the heterozygous
tumor microenvironment. Support for this idea derives
from early findings in GFAP-Cre; Nf1flox/flox mice (harboring
wild-type stromal cells) injected with pTomo-shNf1;shp53
lentivirus. In this respect, the 3 mice that developed
MPNSTs exhibited longer latencies than observed in
GFAP-Cre; Nf1flox/null mice (average of 176 days, Table
1). However, in striking contrast, 50% of the GFAP-Cre;
Nf1flox/null mice injected with pTomo-shNf1;shp53 lentivirus
had developed a limp and exhibited low-grade MPNST
on pathological examination by 50 days post-injection.
Coupled with the results obtained using Periostin-Cre;
Nf1flox/flox mice, it is most likely that cells in the Nf1+/tumor microenvironment provide additional growth
factors or chemokines (e.g., CXCL12 [37]) that accelerate
the growth of the newly-formed MPNST, leading to a
reduced time to clinical symptomatology.
Since the lentivirus employed contained shRNAs
that targeted both the Trp53 and Nf1 genes, we next
sought to determine whether Nf1 shRNA-mediated
KD was sufficient to generate MPNSTs in wild-type or
Nf1+/- mice. Following injection of pTomo-shNf1;shp53
lentivirus at 6 weeks of age, mice were examined 6
months or 12 months later. No mice developed a limp
www.impactjournals.com/oncotarget

and no tumors were appreciated on gross or histologic
examination (Table 1). These findings lend further
support to the hypothesis that loss of Nf1 gene expression
in embryonic Schwann cell precursors is required for
plexiform neurofibroma development and subsequent
MPNST formation, as previously demonstrated by others
[38-40]
The high frequency of MPNSTs in individuals with
NF1 coupled with genetic analyses of human MPNSTs
argues that NF1 loss is an obligate genetic event in MPNST
development. Moreover, the fact that bi-allelic inactivation
of the NF1 gene is observed in most NF1-associated [5,
6, 41] and sporadic [42] MNPSTs supports a critical role
for this tumor suppressor gene in MPNST pathogenesis.
While neurofibromin loss in cells of the Schwann cell
lineage is required for MPNST formation, it is clearly
not sufficient. This lack of sufficiency is nicely illustrated
in Nf1 GEM strains, where mice with conditional Nf1
gene inactivation in Schwann cell precursors alone also
do not develop MPNSTs [10-14], including the GFAPCre; Nf1flox/null and Periostin-Cre; Nf1flox/flox mouse strains
used in the current study. However, the co-existence of
other cooperating genetic events in combination with Nf1
loss does result in MPNST formation (summarized in
Supplemental Table 1). In most of these mouse models,
complex intercrosses of transgenic and conditional
knockout strains are required, and there is no control over
the timing of the acquired somatic genetic event or the
location in which the malignancy will arise [7, 15-20,
43-45]. Using a combination of conditional knockout
mice and lentivirus-mediated somatic p53 inactivation,
we describe an efficient platform for the generation of
MPNSTs. As such, this model is ideally suited to define
the biological importance of somatically-acquired
cooperating genetic events to MPNST pathogenesis,
thus allowing investigators to compare the effects of
known somatic genetic alterations (e.g., p53 versus p16
inactivation) or those identified in large-scale genomic
discovery efforts [46]. In addition, this experimental
system provides both spatial and temporal control. Future
uses of this platform provide opportunities to determine
the impact of introducing cooperating genetic mutations as
a function of mouse age or in different peripheral nerves.
Moreover, since somatic p53 knockdown is directed to
the sciatic nerve, these mice develop a neurologic deficit
(limp), similar to some patients with MPNSTs. The ability
to monitor clinical signs will be important if these models
are employed for preclinical studies.
In summary, the implementation of this
experimental MPNST model system has allowed us to
make two important observations. First, we demonstrate
that somatic reduction, but not absence, of Trp53
expression following Nf1 gene inactivation is sufficient for
MPNST formation. Second, we demonstrate that MPNST
formation can occur in the absence of a microenvironment
composed of cells heterozygous for a germline Nf1 gene
7410
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mutation. Future studies employing this platform may
facilitate more rapid analyses of the contributions of other
cooperating events to MPNST pathogenesis, the role of
the tumor microenvironment in MPNST growth, and the
development of radiologic and molecular biomarkers of
malignant transformation.

Nerves were processed as described above
using primary (Supplemental Table 2) and horseradish
peroxidase-conjugated secondary antibodies (Vector
Laboratories, Burlingame, CA, USA) in combination with
Vectastain Elite ABC development.

MATERIALS AND METHODS

Microscopy
Mice

For eight-week-old GFAP-Cre; Rosa Green and
Periostin-Cre; Rosa Green mouse nerves and bones,
images were acquired at 100x magnification on a
Nikon Eclipse TE300 fluorescence inverted microscope
equipped with an optical camera (Leica DFC 3000G)
and analyzed using Leica Application Suite Advanced
Fluorescence 3.20.9652. Seven day post-injection images
were acquired at 200x magnification on a Nikon Eclipse
TE300 fluorescence inverted microscope equipped with an
optical camera (Leica DFC 3000G). Images from tumor
bearing mice were acquired at 400x magnification using
an Olympus BX51 camera.

GFAP-Cre (FVB-Tg(GFAP-cre)25Mes/J) and RosaGreen reporter mice were purchased from the Jackson
Laboratories [24, 25]. Periostin-Cre [22] and Nf1flox/
flox
[47] mice have previously been described. All mice
were maintained on a C57Bl/6 background and used in
accordance with approved animal studies protocols at the
Washington University School of Medicine.

Lentivirus generation
The pTomo-shNf1;shp53 lentivirus construct used
has been previously described [29]. Viral particles were
produced by the Viral Vectors Core Facility of the Hope
Center for Neurological Diseases at the Washington
University School of Medicine.

Western blotting
Cell pellets, sciatic nerves, or tumors dissected
from sciatic nerves were lysed in buffer containing 1%
NP-40 (nonylphenoxypolyethoxylethanol) supplemented
with protease inhibitors. Western blotting was performed
as previously described [48]. Antibodies used included
neurofibromin (Santa Cruz Biotechnology; dilution 1:100),
p53 (Cell Signaling; dilution 1:1000), and α-tubulin
(Sigma; dilution 1:10000). Densitometry was measured
using Life Science Software from UVP VisionWorks LS
Version 8.1.1 Image Acquisition and Analysis Software
system. α-tubulin serves as an internal protein loading
control.

Sciatic nerve injections
The right flanks of 6-8 week old mice were shaved
and prepped with betadine. The right sciatic nerves were
surgically isolated while mice were under anesthesia.
10μl of pTomo-shNf1;shp53 lentivirus (5x106 IU) or 10μl
vehicle was injected into the right sciatic nerves of mice
using a10μl Hamilton syringe equipped with a 33-gauge
needle. The surgical incision was closed with Vetbond and
sutured. Mice were followed and examined three times per
week until right-sided limping was observed. At this time,
mice were euthanized with carbon dioxide and the sciatic
nerves isolated for gross and histologic analysis.
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